KEGG   DISEASE: Ovarian cancer
Entry
H00027                      Disease                                
Name
Ovarian cancer
Description
Ovarian cancer is the sixth most common cancer and the fifth leading cause of cancer-related death among women in developed countries. Approximately 90% of human ovarian cancer arises within the ovarian surface epithelium (OSE), with the rest originating from granulosa cells or, rarely, stroma or germ cells. Ovarian epithelial tumors are divided into mucinous, serous, endometrioid, and clear cell subtypes. Approximately 10% of ovarian cancers arise in women who have inherited mutations in cancer susceptibility genes (BRCA1 or BRCA2). The vast majority of ovarian cancers are sporadic, resulting from the accumulation of genetic damage over a lifetime. Several specific genes involved in ovarian carcinogenesis have been identified, including the p53 tumor suppressor gene and ERBB2 and PIK3CA oncogenes.
Category
Cancer
Brite
Human diseases [BR:br08402]
 Cancers
  Cancers of the breast and female genital organs
   H00027  Ovarian cancer
Human diseases in ICD-11 classification [BR:br08403]
 02 Neoplasms
  Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues
   Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
    Malignant neoplasms of female genital organs
     2C73  Malignant neoplasms of ovary
      H00027  Ovarian cancer
Tumor markers [br08442.html]
 H00027
Cancer-associated carbohydrates [br08441.html]
 H00027
Related
pathway
hsa04151  PI3K-Akt signaling pathway
hsa04919  Thyroid hormone signaling pathway
Gene
BRCA1 (germline mutation / deletion) [HSA:672] [KO:K10605]
BRCA2 (germline mutation / deletion) [HSA:675] [KO:K08775]
MSH2 (germline mutation) [HSA:4436] [KO:K08735]
MLH1 (germline mutation) [HSA:4292] [KO:K08734]
ERBB2 (amplification / overexpression) [HSA:2064] [KO:K05083]
K-ras (mutation) [HSA:3845] [KO:K07827]
AKT2 (amplification) [HSA:208] [KO:K04456]
PIK3CA (amplification) [HSA:5290] [KO:K00922]
c-MYC (overexpression) [HSA:4609] [KO:K04377]
p53 (mutation / deletion, overexpression) [HSA:7157] [KO:K04451]
CTNNB1 [HSA:1499] [KO:K02105]
PRKN [HSA:5071] [KO:K04556]
OPCML [HSA:4978] [KO:K06773]
AKT1 [HSA:207] [KO:K04456]
CDH1 [HSA:999] [KO:K05689]
Drug
Cyclophosphamide [DR:D00287]
Melphalan [DR:D00369]
Thiotepa [DR:D00583]
Gemcitabine hydrochloride [DR:D01155]
Paclitaxel [DR:D00491]
Topotecan hydrochloride [DR:D02168]
Doxorubicin hydrochloride [DR:D01275]
Bevacizumab [DR:D06409]
Cisplatin [DR:D00275]
Carboplatin [DR:D01363]
Olaparib [DR:D09730] (HRD-positive)
Niraparib tosilate hydrate [DR:D11895]
Rucaparib camsylate [DR:D10982] (BRCA-mutated)
Altretamine [DR:D02841]
Mirvetuximab soravtansine [DR:D10954] (folate receptor alpha positive)
Other DBs
ICD-11: 2C73
ICD-10: C56
MeSH: D010051
OMIM: 167000
Reference
  Authors
Shih IeM, Kurman RJ.
  Title
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.
  Journal
Am J Pathol 164:1511-8 (2004)
DOI:10.1016/S0002-9440(10)63708-X
Reference
  Authors
Katabuchi H, Okamura H.
  Title
Cell biology of human ovarian surface epithelial cells and ovarian carcinogenesis.
  Journal
Med Electron Microsc 36:74-86 (2003)
DOI:10.1007/s00795-002-0196-6
Reference
  Authors
Wenham RM, Lancaster JM, Berchuck A.
  Title
Molecular aspects of ovarian cancer.
  Journal
Best Pract Res Clin Obstet Gynaecol 16:483-97 (2002)
DOI:10.1053/beog.2002.0298
Reference
  Authors
Wright K, Wilson P, Morland S, Campbell I, Walsh M, Hurst T, Ward B, Cummings M, Chenevix-Trench G
  Title
beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours.
  Journal
Reference
  Authors
Denison SR, Wang F, Becker NA, Schule B, Kock N, Phillips LA, Klein C, Smith DI
  Title
Alterations in the common fragile site gene Parkin in ovarian and other cancers.
  Journal
Oncogene 22:8370-8 (2003)
DOI:10.1038/sj.onc.1207072
Reference
  Authors
McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de Sousa C, Greene MI, Wang Q, Agarwal R, Shaposhnikov D, Wong JL, Gungor H, Janczar S, El-Bahrawy M, Lam EW, Chayen NE, Gabra H
  Title
The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer.
  Journal
Cancer Discov 2:156-71 (2012)
DOI:10.1158/2159-8290.CD-11-0256
Reference
  Authors
Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE
  Title
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.
  Journal
Nature 448:439-44 (2007)
DOI:10.1038/nature05933
Reference
  Authors
Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Hofler H, Becker KF
  Title
The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients.
  Journal
Br J Cancer 98:489-95 (2008)
DOI:10.1038/sj.bjc.6604115

» Japanese version

DBGET integrated database retrieval system